Free Trial 中
Wind ESG Rating

Access to ESG rating for China A-Shares and Hong Kong listed companies.

上海莱士

002252.SZ
Wind Industry: 医疗保健 > 医药生物 > 生物科技Ⅲ > 生物科技Ⅳ

公司是在1988年成立的中外合资血液制品大型生产企业，专业从事血液制品，疫苗、诊断试剂及检测器具生产和销售并提供检测服务，主要产品包括人血白蛋白、静注人免疫球蛋白(pH4)、人凝血因子VIII、人凝血酶原复合物、人纤维蛋白原、冻干人凝血酶、外用冻干纤维蛋白粘合剂，公司整体规模为国内血液制品行业领先，是国内同行业中结构合理、产品种类齐全、血浆利用率较高的领先血液制品生产企业。公司目前共有上海、郑州、合肥、温州、南宁5个血液制品生产基地，产品覆盖白蛋白类、免疫球蛋白类及凝血因子三大类，是目前国内少数可从血浆中提取六种组分的血液制品生产企业之一，也是国内同行业中凝血因子类产品种类最为齐全的生产企业之一。

ESG Score Industry Ranking:
2 / 165 (生物科技Ⅲ)

ESG Rating Distribution(生物科技Ⅲ)

Trend of Rating

2022-05-05: BB; 2023-05-02: BB; 2024-06-15: BB; 2025-06-17: AA; 2026-06-05: AA BB2022.05 BB2023.05 BB2024.06 AA2025.06 AA2026.06

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.68Updated on 2026-10-29
08.6810
Management & Practices Score：5.69Updated on 2026-09-17
05.697
Controversies Score：2.99Updated on 2026-10-29
02.993

ESG Score Comparison

Environmental Social Governance 上海莱士生物科技Ⅲ Average
IndicatorCompany ScoreIndustry AverageWeight
Environmental7.753.6712.53%
Social8.124.5457.57%
Governance8.295.7829.91%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

  • 500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
  • 1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB
More Details

Peer Comparison(165 companies in the industry) ?

RankingCodeSecurity NameESG RatingESG ScoreControversies ScoreManagement & Practices ScoreEnvironmentalSocialGovernance
1603392.SH万泰生物AA8.862.965.907.578.548.58
2002252.SZ上海莱士AA8.682.995.697.758.128.29
31801.HK信达生物AA8.623.005.627.788.038.12
4300142.SZ沃森生物AA8.422.945.485.488.148.21
52269.HK药明生物AA8.283.005.288.457.477.29
61530.HK三生制药AA8.262.995.267.567.437.68
7920344.BJ三元基因AA8.162.965.204.337.977.69
7300122.SZ智飞生物AA8.162.975.195.407.428.24
96660.HK艾美疫苗AA8.123.005.126.397.377.57
106855.HK亚盛医药AA8.112.995.127.217.736.59